Diffuse Large B-Cell Lymphoma - Pipeline Review, H2 2016

Date: October 29, 2016
Pages: 710
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: D927DB9DE8AEN
Leaflet:

Download PDF Leaflet

Diffuse Large B-Cell Lymphoma - Pipeline Review, H2 2016
Diffuse Large B-Cell Lymphoma - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diffuse Large B-Cell Lymphoma - Pipeline Review, H2 2016, provides an overview of the Diffuse Large B-Cell Lymphoma (Oncology) pipeline landscape.

Diffuse large B-cell lymphoma, a type of non-Hodgkin lymphoma, is a cancer of B-cells. The lymphoma may metastasize to other organs such as the liver, lungs or the bones. The signs and symptoms of diffuse large B-cell lymphoma may include painless swelling in the neck, armpit or groin caused by enlarged lymph nodes, loss of appetite, tiredness, night sweats, unexplained high temperatures, and weight loss. The possible treatments for diffuse large B-cell lymphoma include radiation, chemotherapy, steroid therapy in combination with chemotherapy, high-dose chemotherapy with stem cell support and monoclonal antibody therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diffuse Large B-Cell Lymphoma - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Diffuse Large B-Cell Lymphoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diffuse Large B-Cell Lymphoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Diffuse Large B-Cell Lymphoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 10, 57, 38, 30 and 5 respectively for Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 5, 2, 1 and 1 molecules, respectively for Diffuse Large B-Cell Lymphoma.

Diffuse Large B-Cell Lymphoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Diffuse Large B-Cell Lymphoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Diffuse Large B-Cell Lymphoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Diffuse Large B-Cell Lymphoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Diffuse Large B-Cell Lymphoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Diffuse Large B-Cell Lymphoma (Oncology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Diffuse Large B-Cell Lymphoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Diffuse Large B-Cell Lymphoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Diffuse Large B-Cell Lymphoma Overview
Therapeutics Development
Diffuse Large B-Cell Lymphoma - Therapeutics under Development by Companies
Diffuse Large B-Cell Lymphoma - Therapeutics under Investigation by Universities/Institutes
Diffuse Large B-Cell Lymphoma - Pipeline Products Glance
Diffuse Large B-Cell Lymphoma - Products under Development by Companies
Diffuse Large B-Cell Lymphoma - Products under Investigation by Universities/Institutes
Diffuse Large B-Cell Lymphoma - Companies Involved in Therapeutics Development
Diffuse Large B-Cell Lymphoma - Therapeutics Assessment
Drug Profiles
Diffuse Large B-Cell Lymphoma - Dormant Projects
Diffuse Large B-Cell Lymphoma - Discontinued Products
Diffuse Large B-Cell Lymphoma - Product Development Milestones
Appendix 695

LIST OF TABLES

Number of Products under Development for Diffuse Large B-Cell Lymphoma, H2 2016
Number of Products under Development for Diffuse Large B-Cell Lymphoma - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Number of Products under Development by Companies, H2 2016 (Contd..2)
Number of Products under Development by Companies, H2 2016 (Contd..3)
Number of Products under Development by Companies, H2 2016 (Contd..4)
Number of Products under Development by Companies, H2 2016 (Contd..5)
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016 (Contd..2)
Products under Development by Companies, H2 2016 (Contd..3)
Products under Development by Companies, H2 2016 (Contd..4)
Products under Development by Companies, H2 2016 (Contd..5)
Products under Development by Companies, H2 2016 (Contd..6)
Products under Development by Companies, H2 2016 (Contd..7)
Products under Development by Companies, H2 2016 (Contd..8)
Products under Development by Companies, H2 2016 (Contd..9)
Products under Investigation by Universities/Institutes, H2 2016
Diffuse Large B-Cell Lymphoma - Pipeline by 3SBio Inc., H2 2016
Diffuse Large B-Cell Lymphoma - Pipeline by AbbVie Inc, H2 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Acetylon Pharmaceuticals, Inc., H2 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Affimed GmbH , H2 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Amgen Inc., H2 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Arrien Pharmaceuticals, LLC, H2 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Arvinas, Inc., H2 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Asana BioSciences, LLC, H2 2016
Diffuse Large B-Cell Lymphoma - Pipeline by AstraZeneca Plc, H2 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Aurigene Discovery Technologies Limited, H2 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Bayer AG, H2 2016
Diffuse Large B-Cell Lymphoma - Pipeline by BeiGene, Ltd., H2 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Biocon Limited, H2 2016
Diffuse Large B-Cell Lymphoma - Pipeline by BioNTech AG, H2 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Boehringer Ingelheim GmbH, H2 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Bristol-Myers Squibb Company, H2 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Celgene Corporation, H2 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Cell Medica Limited, H2 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Cell>Point, L.L.C., H2 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Cellular Biomedicine Group, Inc., H2 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Clevexel Pharma SA, H2 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Constellation Pharmaceuticals, Inc., H2 2016
Diffuse Large B-Cell Lymphoma - Pipeline by CSPC Pharmaceutical Group Limited, H2 2016
Diffuse Large B-Cell Lymphoma - Pipeline by CTI BioPharma Corp., H2 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Curis, Inc., H2 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Cyclacel Pharmaceuticals, Inc., H2 2016
Diffuse Large B-Cell Lymphoma - Pipeline by eFFECTOR Therapeutics, Inc., H2 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Eisai Co., Ltd., H2 2016
Diffuse Large B-Cell Lymphoma - Pipeline by EpiZyme, Inc., H2 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Erytech Pharma SA, H2 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Evotec AG, H2 2016
Diffuse Large B-Cell Lymphoma - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Genentech, Inc., H2 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Genosco, H2 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Gilead Sciences, Inc., H2 2016
Diffuse Large B-Cell Lymphoma - Pipeline by GlaxoSmithKline Plc, H2 2016
Diffuse Large B-Cell Lymphoma - Pipeline by H3 Biomedicine Inc., H2 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Hutchison MediPharma Limited, H2 2016
Diffuse Large B-Cell Lymphoma - Pipeline by ImmunoGen, Inc., H2 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Immunomedics, Inc., H2 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Immunovaccine, Inc., H2 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Incyte Corporation, H2 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Inflection Biosciences Limited, H2 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Innovent Biologics, Inc., H2 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Johnson & Johnson, H2 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Juno Therapeutics Inc., H2 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Karyopharm Therapeutics, Inc., H2 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Kite Pharma Inc, H2 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Mabion SA, H2 2016
Diffuse Large B-Cell Lymphoma - Pipeline by mAbxience S.A., H2 2016
Diffuse Large B-Cell Lymphoma - Pipeline by MedImmune LLC, H2 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Medivation, Inc., H2 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Merck & Co., Inc., H2 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Merck KGaA, H2 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Millennium Pharmaceuticals Inc, H2 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Mirati Therapeutics Inc., H2 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Molplex Ltd., H2 2016
Diffuse Large B-Cell Lymphoma - Pipeline by MorphoSys AG, H2 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Neumedicines Inc., H2 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Nimbus Therapeutics, LLC, H2 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Nordic Nanovector ASA, H2 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Novartis AG, H2 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Pfizer Inc., H2 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Philogen S.p.A., H2 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Portola Pharmaceuticals, Inc., H2 2016
Diffuse Large B-Cell Lymphoma - Pipeline by RedHill Biopharma Ltd., H2 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Respiratorius AB, H2 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Rhizen Pharmaceuticals S.A., H2 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Sandoz International GmbH, H2 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Seattle Genetics, Inc., H2 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Selvita S.A., H2 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Shanghai Henlius Biotech Co., Ltd., H2 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Sigma-Tau S.p.A., H2 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Taiho Pharmaceutical Co., Ltd., H2 2016
Diffuse Large B-Cell Lymphoma - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
Diffuse Large B-Cell Lymphoma - Pipeline by TG Therapeutics, Inc., H2 2016
Diffuse Large B-Cell Lymphoma - Pipeline by TRACON Pharmaceuticals Inc, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Diffuse Large B-Cell Lymphoma - Dormant Projects, H2 2016
Diffuse Large B-Cell Lymphoma - Dormant Projects (Contd..1), H2 2016
Diffuse Large B-Cell Lymphoma - Dormant Projects (Contd..2), H2 2016
Diffuse Large B-Cell Lymphoma - Dormant Projects (Contd..3), H2 2016
Diffuse Large B-Cell Lymphoma - Discontinued Products, H2 2016
Diffuse Large B-Cell Lymphoma - Discontinued Products (Contd..1), H2 2016 697

LIST OF FIGURES

Number of Products under Development for Diffuse Large B-Cell Lymphoma, H2 2016
Number of Products under Development for Diffuse Large B-Cell Lymphoma - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Top 10 Molecule Types, H2 2016
Number of Products by Stage and Top 10 Molecule Types, H2 2016
Skip to top


Mantle Cell Lymphoma - Pipeline Review, H2 2016 US$ 2,000.00 Aug, 2016 · 426 pages
T-Cell Lymphomas - Pipeline Review, H1 2014 US$ 1,500.00 Apr, 2014 · 132 pages
Cutaneous T-Cell Lymphoma - Pipeline Review, H1 2015 US$ 1,600.00 Feb, 2015 · 175 pages
B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H1 2016 US$ 1,700.00 Apr, 2016 · 1066 pages

Ask Your Question

Diffuse Large B-Cell Lymphoma - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: